Postpartum Breast Cancer: Pasteur Institute Research Offers New Prevention Insights

Berlin, Germany – February 20, 2026 – Researchers at the Institut Pasteur in France are exploring a promising new avenue for preventing postpartum breast cancer, a particularly aggressive form of the disease that disproportionately affects younger women. This research, focused on understanding the complex regeneration of breast cells after lactation, could lead to earlier detection and preventative strategies for a cancer that currently poses a significant challenge to women’s health globally.

Breast cancer remains a major public health concern worldwide. According to the World Health Organization (WHO), it represents nearly 12% of all cancer cases globally and has become the most commonly diagnosed cancer worldwide, also being the leading cause of cancer death among women. In developed countries, approximately one in eight women will be diagnosed with breast cancer during their lifetime. The WHO provides comprehensive data and resources on breast cancer, highlighting the urgent need for continued research and improved preventative measures.

The Institut Pasteur’s investigation centers on the period following childbirth, a time when the breast undergoes significant physiological changes. Aurélie Chiche, a researcher at the Institut Pasteur’s unit of cellular plasticity in age-related pathologies, explained that approximately 60,000 new cases of breast cancer are diagnosed annually in France, with 15% affecting women under 45. Alarmingly, half of these younger women are diagnosed with postpartum breast cancer – within five to ten years after a full-term pregnancy, with or without breastfeeding – representing roughly 5,000 cases each year.

The Critical Postpartum Period and Cellular Changes

Preventing postpartum breast cancers is crucial, Chiche emphasizes, because these cancers are particularly aggressive, carrying a three-fold increased risk of metastasis and a poorer prognosis compared to cancers developing at other stages of life. The risk appears to increase with maternal age, as pre-tumor cells accumulate over a woman’s lifetime. This means that, with women in France now having their first child at an average age of 29 – five years later than in 1974 – a growing number of women may be at risk.

While breastfeeding is known to have a protective effect against breast cancer, epidemiological studies over the past two decades have highlighted the postpartum period as a critical window of increased risk, especially for women who give birth after the age of 35. Here’s when the mammary gland, having developed to produce milk, enters a period of ‘involution’ – a process of remodeling, and regression. During this regeneration, certain cells, dubbed ‘phantom cells’ by researchers, cease to proliferate but release molecules that interact with surrounding cells.

The Institut Pasteur team’s research, published in the scientific journal Nature Aging, suggests these ‘phantom cells’ may contribute to an inflammatory environment conducive to tumor development. Specifically, the molecules they produce appear to promote the spread of cancer cells, as demonstrated in studies conducted on mice. Until recently, the underlying mechanisms driving the increased aggressiveness of these tumors remained unclear.

‘Phantom Cells’ and the Inflammatory Response

“Now we know that if a woman already has a pre-cancerous lesion that could have remained latent throughout her life, this period of ‘involution’ can allow these molecules to stimulate the proliferation of pre-cancerous cells,” Chiche explained. This discovery sheds light on why the postpartum period is particularly vulnerable to cancer development.

Experiments on mice have shown that treatments targeting the elimination of senescent, or ‘phantom,’ cells during this involution period can significantly delay tumor onset and reduce metastasis formation. Han Li, who leads the Pasteur team, noted that this finding offers a potential therapeutic strategy for preventing postpartum breast cancer.

Future Directions: Early Detection and Targeted Therapies

However, the research is still in its early stages. Confirming these findings in human tissues and identifying the specific molecules responsible for the increased aggressiveness of cancer cells are crucial next steps. The ultimate goal is to develop a simple blood test to detect these molecules, allowing for better monitoring of women at risk, particularly those who have their first child after age 35 or have a genetic predisposition to breast cancer.

The Institut Pasteur’s work builds on a growing understanding of the complex interplay between hormonal changes, cellular regeneration, and cancer development. Further research is needed to fully elucidate these mechanisms and translate these findings into effective preventative strategies. The potential for targeted therapies that specifically address the inflammatory environment created by ‘phantom cells’ offers a promising new direction in the fight against postpartum breast cancer.

This research underscores the importance of continued investment in breast cancer research and the need for personalized preventative approaches tailored to individual risk factors. Understanding the unique challenges posed by postpartum breast cancer is essential for improving outcomes for young women and reducing the burden of this devastating disease.

Key Takeaways

• Postpartum breast cancer is an aggressive form of the disease affecting younger women.
• ‘Phantom cells’ released during breast tissue regeneration after lactation may contribute to an inflammatory environment that promotes cancer development.
• Research in mice suggests that eliminating these ‘phantom cells’ could delay tumor onset and reduce metastasis.
• The ultimate goal is to develop a blood test to identify women at risk and enable early intervention.

Researchers are continuing to investigate these findings, and further updates will be provided as they become available. For more information on breast cancer prevention and early detection, please consult with your healthcare provider or visit the National Cancer Institute website.

Do you have thoughts on this research? Share your comments below, and please share this article with anyone who might find it helpful.